What is the appropriate treatment for a Staphylococcus epidermidis infection that is susceptible to oxacillin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Oxacillin-Susceptible Staphylococcus epidermidis Infections

For oxacillin-susceptible Staphylococcus epidermidis infections, a β-lactamase-resistant penicillin (such as oxacillin, nafcillin, or cloxacillin) is the treatment of choice, with specific regimens determined by the type and severity of infection.

Antimicrobial Options Based on Susceptibility

The susceptibility results indicate that this S. epidermidis isolate is:

  • Susceptible to oxacillin (indicating it is methicillin-susceptible)
  • Susceptible to ciprofloxacin, levofloxacin, moxifloxacin, linezolid, nitrofurantoin, rifampin, and vancomycin
  • Intermediate to gentamicin
  • Resistant to penicillin, tetracycline, and trimethoprim/sulfa

First-Line Treatment Options

  1. Native Tissue Infections:

    • Oxacillin or nafcillin 8-12 g/24 h IV divided into 3-4 doses for at least 4 weeks for serious infections 1
    • For less severe infections, oral options include dicloxacillin, cloxacillin, or cephalexin
  2. Prosthetic Material/Device-Related Infections:

    • Combination therapy is recommended:
      • Oxacillin or nafcillin 8-12 g/24 h IV divided into 3-4 doses plus
      • Rifampin 900 mg/24 h IV or orally divided into three doses, both for 6-8 weeks
      • Consider adding gentamicin 3 mg/kg/24 h IV for the first 2 weeks if the isolate is susceptible 1

Treatment Algorithms by Infection Type

Uncomplicated Bacteremia/Soft Tissue Infections

  • Oxacillin or nafcillin IV for 10-14 days
  • Alternative: First-generation cephalosporin (cefazolin) if non-immediate penicillin allergy

Endocarditis

  • Native Valve:

    • Oxacillin or nafcillin IV for 4-6 weeks 1
    • Addition of gentamicin for the first 3-5 days is optional but increases risk of toxicity 1
  • Prosthetic Valve:

    • Oxacillin or nafcillin plus rifampin for 6-8 weeks
    • Add gentamicin for the first 2 weeks if susceptible 1

Prosthetic Joint Infection

  • Debridement and retention approach:
    • Initial IV therapy with oxacillin or nafcillin plus rifampin for 2-6 weeks
    • Followed by oral rifampin plus a companion drug (ciprofloxacin preferred based on susceptibilities) 1
    • Total duration: 3 months for hip, 6 months for knee

Alternative Regimens for Penicillin Allergies

For patients with true penicillin allergies:

  • Non-anaphylactic reactions: Cefazolin is appropriate 1
  • Severe allergies: Vancomycin 30 mg/kg/24 h IV divided into two doses 1

Important Clinical Considerations

  1. Avoid cephalosporins for methicillin-resistant strains: Despite in vitro susceptibility results suggesting otherwise, cross-resistance exists 1

  2. Biofilm considerations: For device-related infections, combination therapy with rifampin is crucial due to its activity against biofilm organisms 1

  3. Duration of therapy: Longer courses (4-6 weeks) are required for endocarditis, osteomyelitis, and prosthetic device infections 1

  4. Monitoring: Regular clinical assessment for treatment response is essential

  5. Common pitfalls:

    • Mistaking S. epidermidis as a contaminant when it is a true pathogen
    • Inadequate duration of therapy for deep-seated infections
    • Failure to remove infected devices when necessary
    • Overlooking the need for combination therapy in prosthetic material infections

Special Situations

For urinary tract infections with >100,000 CFU/mL, nitrofurantoin is an appropriate oral option based on the susceptibility results.

For serious infections in patients unable to tolerate β-lactams, vancomycin remains the most reliable alternative, as this isolate shows susceptibility 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.